• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pfizer cuts jobs in Connecticut, adds in Massachusetts

Pfizer cuts jobs in Connecticut, adds in Massachusetts

February 1, 2011
CenterWatch Staff

Boston Business Journal staff report

Pfizer Inc. has announced it will restructure its research and development operation in an effort to save up to $2 billion, and there will be a significant impact to Massachusetts, where the pharmaceutical giant has three facilities - two in Cambridge, Mass., and one in Andover, Mass.

The company plans to relocate its cardiovascular and neuroscience units to a new facility in Cambridge or Boston, from its current hub in Groton, Conn. The company will also exit one of its Cambridge facilities, on Memorial Drive. The company plans to maintain both manufacturing and research and development capabilities in Andover.

In an e-mail to the Boston Business Journal, Pfizer spokeswoman Sperry Mylott wrote, “As part of our new R&D strategy, we intend to shift the global footprint of our R&D network to more fully align with key hubs for science and technology. This will include an expansion of our R&D network in Cambridge, MA.”

Mylott said the transition will take place over the next 18 to 24 months and company officials are negotiating the location of the new site.

“We are committed to treating all colleagues with the utmost respect throughout this process, and to making sure that everyone is informed in an honest, thoughtful and prompt way,” Mylott wrote.

Pfizer said it could create up to 300 new jobs in the state, however it is unclear how many jobs would be lost at the closing Cambridge site.

“Once again, this demonstrates that even when companies are shedding jobs elsewhere, they consider Massachusetts to be an important place to be strategically, and are maintaining or even increasing their presence here. We look forward to working with Pfizer to facilitate their expansion in Cambridge. We will also work with the company to ensure that any workers that are displaced in this transition are provided with appropriate resources to find new employment,” Susan Windham-Bannister, CEO of the Massachusetts Life Sciences Center, said in a statement.

Pfizer currently employs approximately 2300 workers across its three sites.

Some workers will be moved to the new site from Conn, and additional new jobs will be created. However, there will be layoffs in conjunction with the closure of the Memorial Drive site, since Pfizer plans to exit some therapeutic areas, including regenerative medicine, which were the focus of that site.

Pfizer’s cost-cutting comes as the company approaches a so-called “patent cliff”. Some of its most lucrative medications, including Lipitor and Viagra, will soon be opened up to generic competition. The company said Tuesday that sales of Lipitor declined 17 percent in the fourth quarter to $2.63 billion. Sales will decline by more than half next year after generics enter the market in November, company executives said.

Some functions will remain in Groton, including drug safety and toxicology testing.

Read more: Pfizer cuts mean growth, closure in Mass. | Boston Business Journal

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing